Baymatob
Date | Investors | Amount | Round |
---|---|---|---|
N/A | AUD80.0k | Seed | |
N/A | AUD1.5m | Grant | |
N/A | AUD3.0m | Grant | |
* | AUD4.2m | Early VC | |
* | N/A | Grant | |
Total Funding | CAD7.8m |
Related Content
Recent News about Baymatob
EditBaymatob is a pioneering company in the health and AI-guided monitoring sector, focusing on maternity and childbirth. The company operates in the medical technology market, specifically targeting pregnant women and healthcare providers. Baymatob's core product, Oli, is an advanced labor monitoring device designed to dramatically reduce preventable complications and deaths during pregnancy and labor. The device has been granted Breakthrough Device Designation by the U.S. FDA, highlighting its innovative approach to identifying high-risk individuals for postpartum hemorrhage well before it occurs.
Baymatob's business model revolves around selling its proprietary monitoring devices to hospitals and healthcare facilities, generating revenue through direct sales and potential service agreements for device maintenance and data analytics. The company aims to address the alarming maternal mortality rates in the USA and globally, offering a technologically advanced solution to an age-old problem.
Baymatob serves a critical need in the healthcare industry, providing state-of-the-art solutions that are both effective and user-friendly. The company is poised for significant growth, backed by a strong executive team with extensive experience in MedTech and pharmaceuticals.
Keywords: AI-guided, maternal health, neonatal health, labor monitoring, FDA-approved, postpartum hemorrhage, MedTech, healthcare innovation, pregnancy complications, advanced technology.